Registrieren
E-Mail:
Passwort:
Ich akzeptiere die
Nutzungsbedingungen
Registrieren
Registierung erfolgt in Kürze...
query
ai
Login
Registrieren
Infos
Werben auf fleebs.com
Seite indizieren lassen
Einstellungen
Datenschutz
Nutzungsbedingungen
Impressum
Details werden geladen...
https://www.statnews.com/2026/05/21/nih-budget-hearing-3-questions-director-jay-bhattacharya/
Teilen bei
Facebook
Teilen bei
Twitter
Teilen bei
Pinterest
Per Mail empfehlen
NIH Director Jay Bhattacharya: 3 key questions at Senate hearing | STAT
Besides showing skepticism on the budget, senators grilled the NIH director about a leadership vacuum, two viral outbreaks, and the pace of funding.
Ähnliche Seiten
Live coverage: NIH Director Bhattacharya delivers Senate testimony
https://www.statnews.com/2026/05/21/live-coverage-nih-director-jay-bhattacharya-senate-testimony/
David Brat nomination: Former congressman faces US Senate hearing to become ambassador to Australia
https://www.smh.com.au/world/north-america/big-on-tennis-not-on-adelaide-trump-s-ambassador-to-australia-speaks-20260521-p5zzdb.html
Senate Democrats push for first new Medicare benefit in decades| STAT
https://www.statnews.com/2026/05/20/medicare-long-term-care-coverage-new-proposal-senate-democrats/
Judge Rules Partly In Favor Of Luigi Mangione At Key Pretrial Hearing | HuffPost Latest News
https://www.huffpost.com/entry/luigi-mangione-evidence_n_6a0b1cf6e4b09f9ab5795bad
Zenas BioPharma Announces Upcoming Presentation of Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) at EULAR 2026 Congress | The Manila ...
https://www.manilatimes.net/2026/05/19/tmt-newswire/globenewswire/zenas-biopharma-announces-upcoming-presentation-of-results-from-phase-3-indigo-registrational-trial-of-obexelimab-in-immunoglobulin-g4-related-disease-igg4-rd-at-eular-2026-congress/2347035
Uganda: Mbabazi Calls for Unity, Industrial Growth At Kanungu Council Swearing-in - allAfrica.com
https://allafrica.com/stories/202605210731.html
Please enable JavaScript to continue using this application.